CF PharmTech: Closes US$50M Series F Financing
- CF PharmTech, Inc., a Suzhou, China-based maker of inhalation products, raised US $50M in Series F financing
- This followed its US $90M Series E financing in January of 2020, in total, completing an equity investment deal of nearly US $140M within six months
- The investors participated in the Series F financing include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment
- Its existing investors including Passion Capital and Yuanming Capital also participated
- The company also intends to use the funds to accelerate the commercialization of its inhalation products
- Then the company focuses on the development of drugs for the treatment of respiratory diseases in its facilities
